Seval Guldane Cengiz, Ozcan Muhit
Department of Hematology, Ankara University School of Medicine, Ankara 06100, Turkey.
J Clin Med. 2015 Mar 11;4(3):441-59. doi: 10.3390/jcm4030441.
The objectives of this review were to discuss standard and investigational treatment strategies for adolescent and young adult with acute myeloid leukemia, excluding acute promyelocytic leukemia. Acute myeloid leukemia (AML) in adolescent and young adult patients (AYAs) may need a different type of therapy than those currently used in children and older patients. As soon as AML is diagnosed, AYA patient should be offered to participate in well-designed clinical trials. The standard treatment approach for AYAs with AML is remission induction chemotherapy with an anthracycline/cytarabine combination, followed by either consolidation chemotherapy or stem cell transplantation, depending on the ability of the patient to tolerate intensive treatment and cytogenetic features. Presently, continuing progress of novel drugs targeting specific pathways in acute leukemia may bring AML treatment into a new era.
本综述的目的是讨论青少年和青年急性髓系白血病（不包括急性早幼粒细胞白血病）的标准治疗策略和研究性治疗策略。青少年和青年患者（AYA）的急性髓系白血病（AML）可能需要一种与目前用于儿童和老年患者的治疗方法不同的治疗方式。一旦确诊为AML，应让AYA患者参与精心设计的临床试验。AYA-AML的标准治疗方法是采用蒽环类药物/阿糖胞苷联合进行缓解诱导化疗，随后根据患者耐受强化治疗的能力和细胞遗传学特征进行巩固化疗或干细胞移植。目前，针对急性白血病特定通路的新型药物的不断进展可能会将AML治疗带入一个新时代。
